Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Document › Details

Biotie Therapies Corporation. (8/5/11). "Press Release: Biotie Therapies Corporation Interim Report 1 January – 30 June 2011. Acquisition of Synosia Therapeutics, Completion of Phase 3 Trials for Nalmefene in Alcohol Dependence, Successful Share Offering

Organisations Organisation Biotie Therapies Corporation
  Group Acorda Therapeutics (Group)
  Organisation 2 Synosia Therapeutics AG
  Group Acorda Therapeutics (Group)
Products Product nalmefene
  Product 2 SYN-115 (Synosis)
Person Person Veromaa, Timo (BioTie 1998– VP RnD promoted CEO 5/05 before Schering Oy before Collagen Corp)
     


   
Record changed: 2017-04-02

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 650x65px

More documents for Acorda Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px




» top